Balentine LLC’s 10x Genomics TXG Stock Holding History

Balentine LLC’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5,198	Closed	-$291K	–	642
2023 Q4	$291K	Buy	+5,198	New	+$226K	0.01%	398

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Balentine LLC's TXG Position: Q1 2024 in Review

Balentine LLC sold out of 10x Genomics (TXG) in Q1 2024, closing a stake of 5,198 shares — an estimated $291K sold.

Balentine LLC first reported a position in TXG in Q4 2023 and held it in 1 quarter. The position peaked at $291K in Q4 2023. 290 funds tracked by Wall St. Rank hold TXG as of Q1 2024.

Balentine LLC reported no remaining 10x Genomics position as of Q1 2024 after selling out during the quarter.
Balentine LLC sold 5,198 10x Genomics shares in Q1 2024, an estimated $291K.
Balentine LLC first reported a position in 10x Genomics in Q4 2023 and held it in 1 quarter.
Balentine LLC's 10x Genomics position peaked at $291K in Q4 2023.
290 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2024.

Based on Balentine LLC's 13F filing for Q1 2024, filed 15 May 2024.